AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$THC

Fitzgerald Meghan sold (to issuer) $86K of THC

Fitzgerald Meghan sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Fitzgerald Meghan
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides transparency on insider ownership but does not include operational, regulatory, or financial catalysts.

02

Market read

Traders may briefly reassess insider alignment, but the transaction type (sale to issuer) suggests limited fundamental signal.

03

What to watch

No 10b5-1 plan is listed, so traders may scrutinize whether the sale was discretionary; also, the issuer’s buyback mechanics could affect float and liquidity.

Relevance 6/10Timing: Same-day/next-session read-through only; insider Form 4s rarely drive sustained moves without corroborating news.

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare director Fitzgerald Meghan.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Fitzgerald Meghan sold 493 shares to the issuer for about $85.7K at $173.78/share, per SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely noise unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing specifies code D (sale to issuer) and notes no 10b5-1 plan; however, the transaction type is typically mechanical and not tied to new fundamentals.

Market effects

Sector

Minimal; single insider transaction in a healthcare services name does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the director’s sale is part of a broader pattern of trimming, it could slightly increase perceived overhang despite the code D classification.

Key entities

  • issuer
    Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold shares to the issuer (code D).

  • insider
    Fitzgerald Meghan

    Director who sold 493 shares to the issuer at $173.7800/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

THC insider trading history →

Related articles

OCT 5
$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

simplywall.st2 min
SEP 30
$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

theglobeandmail.com2 min
SEP 26
$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

insidermonkey.com3 min
SEP 20
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

simplywall.st3 min
SEP 9
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

simplywall.st2 min